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Introduction
Paroxysmal supraventricular tachycardia (PSVT) 
is a common rhythm disorder (seen in 2.5 per 
1000 adults in the general population) [Ferguson 
and DiMarco, 2003]. It is typically caused by atri-
oventricular (AV) nodal reentry pathway and usu-
ally presents with distinct clinical presentations 
like sudden onset palpitations, anxiety, dizziness, 
shortness of breath, feeling faint and chest tight-
ness. PSVT is usually a well tolerated self-limited 
condition which can easily be controlled by rest, 
vagal maneuvers and alleviating the precipitating 
stimulus. Antiarrhythmic drugs and cardioversion 
may rarely be needed [Kesh Hebbar and Hueston, 
2002; Chan and Yuen, 2006].
Adenosine, an endogenous purine nucleoside, is 
an ultra-short-acting agent with a half life of 1–6 s. 
It interrupts the AV nodal reentry pathway and is 
used as first-line medication in control of PSVT 
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Background: Adenosine is the first-line medication in patients with paroxysmal 
supraventricular tachycardia. Because it is cleared so rapidly from the circulation, recurrence 
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Objective: This study was conducted to evaluate the role of oral verapamil administration 
to control early recurrences of paroxysmal supraventricular tachycardia after adenosine 
infusion.
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received an adenosine protocol (6 mg rapid bolus intravenous injection followed by two 
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any other medications but patients in the adenosine/verapamil group received 40 mg 
verapamil orally immediately after converting the rhythm to sinus rhythm. All patients were 
followed up for 6 h in the acute care area of the emergency department under continuous 
cardiac monitoring.
Results: A total of 113 patients were assessed for eligibility and 92 patients were randomized 
into two groups (adenosine only versus adenosine/verapamil). There was no statistically 
significant difference in paroxysmal supraventricular tachycardia recurrence rate between the 
two groups in the first 30 min after treatment. Recurrence rate was statistically significantly 
lower in the adenosine/verapamil group than in the adenosine-only group between 30 and 120 
min after treatment and thereafter. Two patients in the adenosine-only group experienced 
flushing and one patient in the adenosine/verapamil group experienced decreased systolic 
blood pressure.
Conclusion: Oral verapamil can decrease paroxysmal supraventricular tachycardia recurrence 
after successful control with intravenous adenosine.
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[Nolan et al. 2005]. Adenosine is cleared so rapidly 
from circulation (mainly by erythrocyte and vascu-
lar endothelial cell uptake) and PSVT may recur 
after initial successful conversion by adenosine 
[DiMarco, 2000]. Thus any complementary treat-
ment which can reduce the rate of recurrence in 
successfully controlled PSVT cases is of interest.
Verapamil is a calcium channel blocker which 
inhibits calcium ion influx in direct proportion to 
its concentration in plasma. It has a bioavailability 
of 20–35% and plasma half life of 3–6 h, reaches its 
peak plasma level in 1–2 h, has no or few active 
metabolites and is eliminated by extra-renal routes. 
Verapamil can decrease the rate of sinus node dis-
charges and slow down AV node conduction while 
maintaining the normal function of His-Purkinje 
fibers and ventricular myocardial cells, thus it is 
used to control atrial arrhythmia [McAllister et al. 
1983; Burkart, 1992; McTavish, 1989].
This prospective randomized clinical trial was 
conducted to evaluate the efficacy of oral vera-
pamil in decreasing the early recurrence rate of 
PSVT after successful control with intravenous 
adenosine in the emergency department.
Materials and methods
Study design and setting
This randomized clinical trial with convenient 
recruitment of patients during October 
2010–August 2011 was conducted in a tertiary 
teaching hospital with a total annual census of 
45,000 adult patients. The study was approved by 
the institutional ethics committee. Informed writ-
ten consent was obtained from all patients and 
the trial was registered [ClinicalTrials.gov identi-
fier: NCT01655316].
Participants
We included patients aged at least 18 years who 
were admitted to the emergency department with 
suspected PSVT [based on their rapid onset of 
symptoms and electrocardiogram (ECG) evi-
dence of regular narrow complex tachycardia] 
who had not received any antiarrhythmic drugs 
before emergency department presentation and 
whose condition failed to respond to vagal 
maneuvers.
We excluded patients with hemodynamic instabil-
ity (chest pain, decreased level of consciousness, 
hypotension or pulmonary edema due to conges-
tive heart failure); known cases of Wolf–Parkinson–
White syndrome (WPW) or structural heart 
disease; patients with known ischemic heart dis-
ease; patients with known allergy to adenosine or 
verapamil; patients with a contraindication to 
verapamil or adenosine (any evidence of severe 
heart failure, sick sinus syndrome, second- or 
third-degree AV block, WPW, history of asthma, 
heart transplantation, hypersensitivity to adeno-
sine or verapamil).
Intervention
Patients with PSVT were triaged to the cardiopul-
monary resuscitation room. They first underwent 
vagal maneuvers under cardiac monitoring. If the 
maneuvers were unsuccessful patients were 
included in our study.
All patients received 6 mg adenosine as a rapid 
bolus intravenous injection by the peripheral 
route followed by a rapid saline flush. If the first 
dose did not eliminate the PSVT within 1–2 min, 
12 mg adenosine was administered intravenously 
again and then this 12 mg dose was repeated for a 
second time if required.
When the PSVT was controlled and the rhythm 
converted to sinus rhythm, patients were ran-
domly allocated to the adenosine-only or the 
adenosine/verapamil group. We used computer-
generated randomization blocks of four to make 
random allocation. Patients whose rhythm did 
not convert to sinus rhythm with adenosine were 
excluded from the study and other antiarrhyth-
mic drugs were used.
Patients in the adenosine-only group did not 
received any other medications but patients in the 
adenosine/verapamil group received 40 mg vera-
pamil orally immediately after the rhythm was 
converted to sinus rhythm.
All patients were followed up for 6 h in the acute 
care area of the emergency department under 
continuous cardiac monitoring. If the rhythm on 
the monitor changed, an ECG tracing was taken 
immediately and if the new ECG showed the 
recurrence of PSVT, the patient was treated 
accordingly.
Any evidence of verapamil or adenosine side 
effects (including excessive bradycardia, hypoten-
sion, nausea, vomiting, abdominal pain, headache, 
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dizziness, itching, trouble breathing, chest pain 
and flushing) was documented.
Measurements
Any evidence of rhythm disturbance was detected 
on continuous cardiac monitoring and was veri-
fied by immediate ECG tracing. Serial blood 
pressure control was done every 5–10 min by 
noninvasive blood pressure monitoring. Baseline 
vital signs and ECG findings were recorded before 
intervention and then 30 and 120 min after 
rhythm control with adenosine and verapamil 
intake. Early adverse effects of verapamil, includ-
ing respiratory difficulties, circulatory compro-
mise (more than 20 mmHg decrease in systolic 
blood pressure), dizziness, nausea and vomiting, 
itching, headache and hypersensitivity reactions 
were immediately recorded.
The primary outcome measure was the rate of 
maintaining sinus rhythm within 2 h after suc-
cessful cardioversion and the secondary outcome 
was the occurrence of adverse effects of drugs.
Data analysis
Descriptive data are presented as minimum, max-
imum and mean (with standard deviation). We 
used Student’s t test or the χ2 test to compare 
means. All data analyses were performed with 
SPSS version 16 (SPSS, Inc., Chicago, IL, USA).
Results
Basic characteristics of study patients
There was no statistically significant difference in 
demographic characteristics and comorbid condi-
tions between the two groups. There was also no 
statistically significant differences in baseline vital 
signs of patients including systolic and diastolic 
blood pressure, heart rate, respiratory rate and 
oxygen saturation between the two groups (Table 
1). The flow of study subjects is illustrated as the 
CONSORT diagram (Figure 1).
Main results
In the first 30 min after treatment, PSVT recurred in 
4 (8%) patients in the adenosine-only group and in 
10 (21%) patients in the adenosine/verapamil group. 
There was no statistically significant difference in 
PSVT recurrence rate between the two groups in the 
first 30 min after treatment (p = 0.078).
Between 30 and 120 min after adenosine therapy, 
PSVT recurred in 21 (45%) patients in the aden-
osine-only group and in 13 (28%) patients in the 
adenosine/verapamil group. The recurrence rate 
was statistically significant lower in the adenosine/
verapamil group than in the adenosine-only group 
(p = 0.042) between 30 and 120 min after treat-
ment. In the rest of the follow-up period no fur-
ther recurrence was seen in the two groups.
Complications
Two patients in the adenosine-only group experi-
enced flushing and one patient in the adenosine/
verapamil group experienced decreased systolic 
blood pressure.
Discussion
Maintaining the sinus rhythm in patients after 
successful rhythm conversion is an ideal goal in 
any acute cardiac care setting. PSVTs are suc-
cessfully converted to sinus rhythm in emergency 
departments by applying vagal maneuvers, allevi-
ating the precipitating factor and administrating 
adenosine. Adenosine is highly effective in PSVT 
control (especially PSVTs with fast rates) [Ballo 
et al. 2004], converting 60% of PSVTs to normal 
sinus rhythm within 1 min after a bolus injection 
of 6 mg and 92% after a bolus injection of 12 mg. 
Adenosine has rare side effects which usually 
resolve in less than 60 s [Blomstrom-Lundqvist et 
al. 2003]. Adenosine has been used safely in 
PSVT control in prehospital settings too [Gausche 
et al. 1994; McCabe et al. 1992]. Most adenosine-
controlled PSVTs are feasibly maintained in sinus 
rhythm in acute care settings but there are still 
some cases of early recurrence. Different studies 
have been conducted to find better therapeutic 
modalities with a lower recurrence rate but stud-
ies on oral agents are rare.
Our study showed that oral verapamil can decrease 
the early recurrence of PSVT (after its successful 
control with intravenous adenosine) effectively 
while showing no significant adverse reactions. This 
can be due to enhanced negative chronotropic 
effects on the AV node resulting from interrupted 
AV nodal reentry pathways (adenosine effect) and 
reduced sinus node rate and AV nodal conduction 
(verapamil effect) [DiMarco, 2000; McAllister et al. 
1983; Burkart, 1992; McTavish, 1989].
This negative chronotropic effect of calcium 
channel blockers (including verapamil) is 
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Table 1. Baseline data of patients in adenosine-only and adenosine/verapamil groups.
Variable All patients  
(n = 92)
Adenosine only  
(n = 46)
Adenosine/
verapamil (n = 46)
p value
Age, mean (±SD), years 53.47 (±13.99) 50.22 (±14.56) 56.72 (±12.74) 0.14*
Sex, n (%) 0.83$
 Male 53(57.6) 26 (56.5) 27 (58.6)
 Female 39 (42.3) 20 (43.7) 19 (41.3)
Heart rate, beat per min 162.7 (±11.0) 162.9 (±9.8) 162.9 (±10.7) 0.85*
Systolic blood pressure, mean (±SD), 
mmHg
113.7 (±13.9) 114.4 (±12.44) 112.6 (±15.3) 0.76*
Diastolic blood pressure, mean (±SD), 
mmHg
80.4 (± 9.9) 82.2 (± 10.4) 78.5 (±9.2) 0.33*
Respiratory rate, mean (±SD), 
respiration per min
13.6 (±1.4) 13.6 (±1.6) 13.6 (±1.3) 0.14*
Arterial O2 saturation, mean (±SD), % 97.5(±0.6) 97.5 (±0.6) 97.3 (±0.7) 0.41*
Comorbid condition, n (%) 0.26$
 Diabetes mellitus 26 (28.2) 14 (30.4) 12 (26.0)  
 Hypertension 34 (36.9) 18 (19.5) 16 (34.7)  
 Ischemic heart disease 41(44.5) 20 (43.4) 21 (45.6)  
 Obstructive lung disease 30 (32.6) 12 (26.0) 18 (39.1)  
*Student’s t test.
$χ2 test.
113 patients were assessed for eligibility
46 patients were allocated to
adenosine-only group and they received:
6 mg adenosine as rapid bolus infusion plus 
one or two other 12 mg doses of adenosine 
if required 
92 patients were randomized
21 excluded:
11 had hemodynamic instability 
1 had structural heart disease 
5 showed ischemic changes in 
ECG after conversion to sinus 
rhythm 
4 had evidence of severe heart failure 
0 lost to follow up: 
46 patients were analyzed
(0 excluded from analysis)
0 lost to follow up: 
46 patients were analyzed
(0 excluded from analysis)
46 patients were allocated to 
adenosine/verapamil group and they received:
6 mg adenosine as rapid bolus infusion plus 
one or two other 12 mg doses of adenosine 
if required + 40 mg oral verapamil 
                  Figure 1. CONSORT diagram showing patient flow in study.  
                 ECG, electrocardiogram.
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relatively well known and most studies have 
shown that intravenous verapamil has similar effi-
cacy to adenosine in PSVT control [Mangrum 
and DiMarco, 2002; DiMarco, 2000]. There are 
also other studies evaluating the role of the nega-
tive chronotropic effect of calcium channel block-
ers in PSVT control by focusing on their 
self-administration during well tolerated PSVT 
attacks. For example, a study on self-administra-
tion of a single dose of diltiazem/propranolol at 
the time of arrhythmia onset showed that this oral 
antiarrhythmic regimen can control infrequent, 
long-lasting and well tolerated PSVTs effectively, 
safely leading to decreased emergency room 
admissions [Alboni et al. 2001].
In another study by Yeh and colleagues a single 
oral dose of 120 mg diltiazem plus 160 mg pro-
pranolol terminated the electrically induced PSVT 
in 14 (93%) of 15 cases within 3 h of drug admin-
istration. In addition, 50 of 51 PSVT episodes 
occurring during 5 ± 1 months of follow up were 
converted within 3 h (conversion time 21 ± 16 
min) after a single diltiazem plus propranolol oral 
dose with no major drug-related adverse effects 
[Yeh et al. 1985]. There are similar studies with 
other antiarrhythmic drugs like flecainide [Musto 
et al. 1992]. Some other studies have used calcium 
channel blockers to control the ventricular rate in 
patients with chronic atrial flutter or atrial fibrilla-
tion (in conjunction with digoxin) and in prophy-
laxis of repetitive paroxysmal supraventricular 
tachycardia [Mangrum and DiMarco, 2002].
Contrary to our study, Hamer and colleagues 
showed in their study of 10 patients with PSVT 
that oral verapamil could terminate the PSVT in 
one patient after 40 min and in two other patients 
after 90 min. They also did nuclear studies to 
evaluate oral verapamil absorption during PSVT 
and showed that gastric emptying time was 
increased during PSVT and serum verapamil 
level was lower in patients with PSVT than in 
patients with sinus rhythm [Hamer et al. 1987].
Limitations
The most important limitation in our study is that 
we did not used placebo. Other placebo-con-
trolled studies may be more beneficial in identify-
ing the role of oral verapamil in PSVT early 
recurrence control in the emergency department. 
Another limitation may be that we have only stud-
ied verapamil but not other calcium channel 
blockers like diltiazem. Our follow-up period is 
limited to 6 after administration and more pro-
longed follow ups may be considered in other 
studies. We have used the oral form of verapamil 
but the crushed sublingual form may be used too. 
According to some studies different factors like 
age, baseline heart rate and systolic blood pres-
sure, known heart disease and rhythms encoun-
tered after adenosine administration can influence 
the recurrence of PSVT after its control with 
intravenous adenosine [Chun et al. 2002; 
Morrison et al. 2001; Luber et al. 2001] but we 
did not evaluate the role of these factors in our 
study.
Although our results showed that recurrence rates 
in the first 30 min after treatment were not statis-
tically significant different in the two treatment 
groups (p = 0.07), this difference may be clini-
cally important and shows a trend in the adeno-
sine-only group to be better controlled. Oral 
verapamil reaches its peak plasma level 1–2 h after 
administration [John et al. 1992], thus the insig-
nificance in PSVT control during the first 30 min 
could be due to the negligible blood level of vera-
pamil, but we have no explanation for the better 
control of arrhythmia in the adenosine-only 
group. This could be an accidental finding and 
other more controlled studies are needed to clar-
ify the true difference.
Conclusion
Adding oral verapamil to intravenous adenosine is 
an effective and safe approach to decreasing the 
early recurrence rate of PSVTs controlled with 
adenosine in the acute cardiac care setting. This 
therapeutic modality could help acute care physi-
cians be more confident about maintaining the 
achieved sinus rhythm in successfully converted 
PSVTs.
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